more_reports

Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough

  ()
Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential.
Tags: Biotechnology / Pharmaceuticals

The World's First AI Voice Detection For Drugs & Alcohol With Charts That Beckon Investors To Buy

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson explains why he thinks MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is a Speculative Buy.
Tags: Medical DevicesLife Sciences Tools & Diagnostics

Biotech Company Uncovers Breakthrough Canine Arthritis Treatment

  ()
Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why.
Tags: Biotechnology / Pharmaceuticals

Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data

Research Report
  ()
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics.
Tags: Biotechnology / Pharmaceuticals

Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough

  ()
Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) early results reveal dose-dependent drug exposure and significant biomarker reductions for forms of muscular dystrophy.
Tags: Biotechnology / Pharmaceuticals

First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands

  ()
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is opening its inaugural brain PET clinic in Florida with a five-year lease and renewal option.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Biotech Company Achieves Key Bladder Cancer Milestone in California

  ()
ImmunityBio Inc. (IBRX:NASDAQ) confirms study power sufficiency for ANKTIVA combo, supporting measurable response outcomes and maintaining timeline for 2026 BLA filing.
Tags: Biotechnology / Pharmaceuticals

Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline

Research Report
  ()
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry.
Tags: Biotechnology / Pharmaceuticals

America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors?

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson explains why he thinks Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is a Strong Speculative Buy.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track

Research Report
  ()
Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report.
Tags: Biotechnology / Pharmaceuticals

Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Accelerates AI Detection Breakthrough Globally

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity

  ()
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts.
Tags: Biotechnology / Pharmaceuticals

Life Sciences Firm Advances Massive US$2.4B Market Opportunity

  ()
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA).
Tags: TechnologyBiotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands

Research Report
  ()
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

A New Infection Control Platform Launched

Contributed Technical Analyst Opinion
  ()
John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy.
Tags: Biotechnology / PharmaceuticalsAlternative - Cleantech

Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data

Research Report
  ()
Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy.
Tags: Biotechnology / Pharmaceuticals

Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential

  ()
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%.
Tags: NutraceuticalsBiotechnology / Pharmaceuticals

Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"

Research Report
  ()
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts.
Tags: Medical Devices